Hal W. Hirte

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Roger Stupp, Sophie Taillibert, Andrew A. Kanner et al. · JAMA · 2017 · 2.6K citations · Full text

Medicine, Neurosurgery, Oncology +16

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

James Perry, Normand Laperrière, Christopher J. O’Callaghan et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Karen A. Gelmon, Marc Tischkowitz, Helen Mackay et al. · The Lancet Oncology · 2011 · 1.1K citations

Medicine, Gynecology, Oncology +17

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Jacobus Pfisterer, Marie Plante, Ignace Vergote et al. · Journal of Clinical Oncology · 2006 · 751 citations · Full text

Medicine, Oncology, Pharmacology +17